This experimental data make the previous results even more interesting, since bevacizumab would block the effect of increased VEGF before any receptor activation, and it is not clear what would be the role of this VEGF-erythropoietin pathway in chronic anemic patients such as HHT patients. Here, EPO is linked to hereditary hemorrhagic telangiectasia.